セラノスティクスの世界市場

「セラノスティクスの世界市場 – Theranostics: Global Markets」は世界のセラノスティクス市場を主要セグメント別に分析・予測したBCC Researchの市場調査報告書です。

セラノスティクス関連企業については、収益、製品ポートフォリオ、最近の活動などの企業概要に加え、競合状況、市場動向、市場促進要因、阻害要因、市場機会などの市場力学についても解説しています。調査対象としては、セラノスティクス機器にはPET/CT、SPECT/CTなどが含まれ、またセラノスティクス作用薬は診断薬と治療薬が含まれます。対象地域は、北米、欧州、アジア太平洋地域、その他の地域（RoW）です。その他、主要地域別や用途別での分析・予測も行っています。

主な掲載内容

• 市場概観
  • PESTLE分析
  • ファイブフォース分析
  • R&Dと規制当局の承認
  • 医薬品開発プロセス
  • セラノティクス向け治験
• 市場力学
  • 市場力学
  • 市場成長促進要因
  • 市場成長阻害要因
  • 市場の課題
  • 市場機会
• 新技術＆発展
  • セラノティクスにおける人工知能
• 市場セグメント別分析
  • 製品タイプ別セラノティクス市場分析
  • 用途別セラノティクス市場分析
  • 地域分類
  • 地域別セラノティクス市場分析
• 競合情報
  • 戦略分析
  • 治験分析
• セラノティクス市場におけるサステナビリティ：ESGパースペクティブ
  • セラノティクス市場における重要ESG問題
  • セラノティクス市場におけるESGの最新状況
  • ESGの実績分析

Report Overview

Report Scope:

This report provides a comprehensive summary of the theranostics market. It profiles all the major companies present in the market, including revenues, product portfolios and recent activities. It examines the competitive landscape, market trends and market dynamics such as drivers, restraints and opportunities. The report provides historic, current and projected market value. By product type, the market is segmented into theranostics equipment and theranostics agents. Theranostics equipment includes PET/CT, SPECT/CT and others; the theranostics agents studied are diagnostics and therapeutics agents. The regions considered are North America, Europe, Asia-Pacific, and the Rest of the World. The top countries in each region are also profiled. The market is also segmented by application.

Report Includes:

-45 data tables and 37 additional tables
– An overview of the global markets for theranostics
– Analysis of trends in the global market for theranostics, with revenue data for 2021-2023, estimated figures for 2024, forecasts for 2029, and projected CAGRs through 2029
– Evaluation of the current market size and revenue growth prospects specific to theranostics, along with a market share analysis by product type, application, and region
– Assessment of current applications for theranostics and emerging applications such as macular degeneration, gynecology, cutaneous hypersensitivity and cardio-respiratory medicines
– Identification of technological and industry trends in each market segment, as well as the manufacturers of products used in theranostics, reagents and instrumentation for theranostics research, as well as suppliers of theranostics-related services
– Assessment of global R&D activity related to theranostics, resulting in the issuance of patents
– A discussion of ESG challenges and ESG practices in the industry
– Analysis of the key companies’ market shares, proprietary technologies and strategic alliances
– Profiles of the leading players, including GE Healthcare, Siemens Healthineers AG, Novartis, Lantheus and Telix Pharmaceuticals Ltd.

Executive Summary

Summary:

Theranostics is a combination of therapeutics and diagnostics. The main aim of theranostics is to provide diagnostics and therapeutics together in order to personalize treatment. The term was first coined by John Funkhouser in 1998. Theranostics is a prime example of personalized medicine. Radiotheranostics are applied via radionuclides, as they have properties for diagnosis and therapeutics. The primary application of theranostics is in the field of oncology.

The theranostics market is relatively new, being only about two decades old. A significant driver for theranostics is the inherent disadvantages of conventional cancer treatment. Chemotherapy has been the most widely used form of cancer treatment and is the first line of treatment for many cancers. However, chemotherapy has many disadvantages, such as adverse effects on healthy cells, loss of effectiveness on cancer cells and lack of a way to provide personalized treatment. With the help of theranostics, customized treatment can be provided to the patient, which helps overcome chemotherapy’s limitations and side effects.

One of the major factors driving the theranostics market is the rising number of cancer cases in both developed and developing countries. Cancer cases are on the rise in developed countries due to the population aging and earlier and more effective screening. In contrast, cancer cases are increasing in developing countries due to growth in overall population and changing lifestyles. On the other hand, the cancer mortality rates have been declining in many regions and countries. The declining mortality rates are due to advancements in cancer treatment and early detection. Nonetheless, the rising number of cancer patients will lead to a demand for new and better technology that effectively treats the disease and improves patients’ quality of life. This is possible through theranostics.

The market is faced with challenges and restraints that are holding the market back. One of the significant challenges of theranostics is the cost of treatment. Theranostics employs high-end equipment and reagents. Compared to other cancer treatments, the cost of theranostics procedures can be very high due to the involvement of many experts. It is one of the significant reasons for slow adoption, particularly in cost-sensitive markets.

Another challenge is the failure of some early radiotherapeutics. The current theranostics market is based on radionuclides. Commercial failure of these drugs has significantly hindered the market’s growth. Investors may be hesitant due to a lack of return on investments.

The major opportunity in the market is for treating cancer, particularly prostate cancer and neuroendocrine tumors. Theranostics can also be applied to other cancers. Radionuclides are conjugated with antibodies, proteins and other biomarkers to achieve targeted radionuclide therapy.

Frequently Asked Questions (FAQs)

What is the projected market size and growth rate of the market?

The global market for theranostics market is valued at $3.7 billion in the year 2023 and is expected to reach $12.7 billion by 2029, at a growth rate of 24.0% from 2024 to 2029.

What are the key factors driving the growth of the market?

• Growing cancer patient.
• Increasing costs of Drug Discovery.
• Resistant to existing cancer treatment.

What segments are covered in the market?

The theranostics market has been studied by type, by region and by application.

By Application, which segment will dominate the market by the end of 2029?

Prostate cancer will continue dominating the theranostics market in 2029.

Which region has the highest market share in the market?

North America holds the highest share in the market.

Table of Contents

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview

Overview
PESTLE Analysis
Political
Economic
Social
Technological
Legal
Environmental
Porter’s Five Forces Analysis
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential of New Entrants
Competition in the Industry
Threat of Substitutes
R&D and Regulatory Approval
The Drug Development Process
Drug Discovery
Preclinical Development
Clinical Trials
The New Drug Application Review
NDA Data Review
Clinical Trials for Theranostics
Steps Followed for Radiotherapeutics in Clinical Trials

Chapter 3 Market Dynamics

Market Dynamics
Market Drivers
Theranostics Replacing Conventional Treatment
Increased Application of Theranostics in Drug Discovery
Prevalence of Chronic Diseases is Increasing the Demand for Personalized Treatment
New Radiotheranostics Driving the Theranostics Market
Rise in Chronic Inflammatory Diseases
Cancer Epidemics in Developing Countries
Market Restraints
High Cost of Theranostics
Market Challenges
Nanotheranostics-Bio Interactions
Challenges of Radiotheranostics
Failure of Radiotherapeutics
Market Opportunities
Theranostics in Cardiovascular Diseases

Chapter 4 Emerging Technologies and Developments

Artificial Intelligence in Theranostics
Drug Delivery Using Innovative Material
Boron Neutron Capture Therapy (BNCT)
Luminogen Aggregation-Induced Emission (AIE)
Theranostics in Rheumatoid Arthritis (RA)

Chapter 5 Market Segmentation Analysis

Segmentation Breakdown
Market Analysis, by Product Type
Theranostics Equipment
Theranostics Agents
Diagnostics Theranostics Agents
Therapeutics Theranostics Agents
Market Analysis, by Application
Etiology of Cancer
Cancer Diagnosis
Cancer Therapeutics
Prostate Cancer
Neuroendocrine Tumors
Thyroid Cancer
Neuroblastoma
Other Diseases
Geographic Breakdown
Market Analysis, by Region
North America
Europe
Asia-Pacific
Rest of the World

Chapter 6 Competitive Intelligence

Strategic Analysis
Clinical Trials Analysis

Chapter 7 Sustainability in Theranostics Market: An ESG Perspective

Introduction to ESG
Key ESG Issues in the Theranostics Market
Safety of Personnel
Disposal of Radioactive Waste
Nanopollution
Current Status of ESG in the Theranostics Market
ESG Performance Analysis
Concluding Remark from BCC Research

Chapter 8 Appendix

Methodology
Sources
Acronyms

Company Profiles

BAYER AG
CURIUM PHARMA
GE HEALTHCARE
LANTHEUS
NOVARTIS AG
SIEMENS HEALTHINEERS AG
TELIX PHARMACEUTICALS LTD.
Other Companies

List of Tables

Summary Table : Global Market for Theranostics, by Product Type, Through 2029
Table 1 : Approved Radiopharmaceuticals for Radiotheranostics, 2024
Table 2 : Worldwide Regulatory Authorities, 2024
Table 3 : Dosimetry Pre-therapy and Post-therapy
Table 4 : Global Market for Theranostics, by Product Type, Through 2029
Table 5 : Global Market for Theranostics Equipment, by Type, Through 2029
Table 6 : Global Market for Theranostics Equipment, by Region, Through 2029
Table 7 : Global Market for PET Theranostics Equipment, by Region, Through 2029
Table 8 : Global Market for SPECT Theranostics Equipment, by Region, Through 2029
Table 9 : Global Market for MRI Theranostics Equipment, by Region, Through 2029
Table 10 : Global Market for Other Theranostics Equipment, by Region, Through 2029
Table 11 : Global Market for Theranostics Agents, by Type, Through 2029
Table 12 : Global Market for Theranostics Agents, by Region, Through 2029
Table 13 : Select Theranostics Pair
Table 14 : Properties of Commonly Used Radionuclides in Theranostics
Table 15 : Global Market for Diagnostics Theranostics Agents, by Region, Through 2029
Table 16 : Difference Between Alpha Particles and Beta Particles
Table 17 : Global Market for Therapeutics Theranostics Agents, by Region, Through 2029
Table 18 : Lu-177 Based Active, Completed and Recruiting Studies in the U.S., 2023
Table 19 : Advantages and Disadvantages of Various Cancer Treatments
Table 20 : Global Market for Theranostics Applications, by Type, Through 2029
Table 21 : Global Market for Prostate Cancer Applications in Theranostics, by Region, Through 2029
Table 22 : Global Market for Neuroendocrine Tumor Applications in Theranostics, by Region, Through 2029
Table 23 : Global Market for Thyroid Cancer Applications in Theranostics, by Region, Through 2029
Table 24 : Global Market for Neuroblastoma Applications in Theranostics, by Region, Through 2029
Table 25 : Global Market for Other Disease Applications in Theranostics, by Region, Through 2029
Table 26 : Estimated Number of Cancer Deaths Per Region, 2022 and 2045
Table 27 : North American Market for Theranostics, by Product Type, Through 2029
Table 28 : North American Market for Theranostics Equipment, by Type, Through 2029
Table 29 : North American Market for Theranostics Agents, by Type, Through 2029
Table 30 : North American Market for Theranostics Applications, by Type, Through 2029
Table 31 : North American Market for Theranostics, by Country, Through 2029
Table 32 : Theranostics Centers Needed in the U.S.
Table 33 : European Market for Theranostics, by Product Type, Through 2029
Table 34 : European Market for Theranostics Equipment, by Type, Through 2029
Table 35 : European Market for Theranostics Agents, by Type, Through 2029
Table 36 : European Market for Theranostics Applications, by Type, Through 2029
Table 37 : European Market for Theranostics, by Country, Through 2029
Table 38 : Asia-Pacific Market for Theranostics, by Product Type, Through 2029
Table 39 : Asia-Pacific Market for Theranostics Equipment, by Type, Through 2029
Table 40 : Asia-Pacific Market for Theranostics Agents, by Type, Through 2029
Table 41 : Asia-Pacific Market for Theranostics Applications, by Type, Through 2029
Table 42 : Asia-Pacific Market for Theranostics, by Country, Through 2029
Table 43 : Rest of the World Market for Theranostics, by Product Type, Through 2029
Table 44 : Rest of the World Market for Theranostics Equipment, by Type, Through 2029
Table 45 : Rest of the World Market for Theranostics Agents, by Type, Through 2029
Table 46 : Rest of the World Market for Theranostics Applications, by Type, Through 2029
Table 47 : Market Ranking, Theranostics Agents
Table 48 : Strategic Analysis: Theranostics Market, 2021–2024
Table 49 : Targeted Radioligands Therapy in Clinical Trials, 2024
Table 50 : The Three Pillars of ESG
Table 51 : ESG Ranking of Leading Theranostics Players
Table 52 : ESG Performance and Goals of Various Companies in the Theranostics Market Across Parameters
Table 53 : Report Information Sources
Table 54 : Major Acronyms Used in the Global Theranostics Market
Table 55 : Bayer AG: Company Snapshot
Table 56 : Bayer AG: Financial Performance, FY 2022 and 2023
Table 57 : Bayer AG: Product Portfolio
Table 58 : Bayer AG: News/Key Developments, 2021–2023
Table 59 : Curium Pharma: Company Snapshot
Table 60 : Curium Pharma: Product Portfolio
Table 61 : GE Healthcare: Company Snapshot
Table 62 : GE Healthcare: Financial Performance, FY 2022 and 2023
Table 63 : GE Healthcare: Product Portfolio
Table 64 : GE Healthcare: News/Key Developments, 2023–2024
Table 65 : Lantheus: Company Snapshot
Table 66 : Lantheus: Financial Performance, FY 2022 and 2023
Table 67 : Lantheus: Product Portfolio
Table 68 : Lantheus: News/Key Developments, 2023–2024
Table 69 : Novartis AG: Company Snapshot
Table 70 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 71 : Novartis AG: Product Portfolio
Table 72 : Novartis AG: News/Key Developments, 2022
Table 73 : Siemens Healthineers AG: Company Snapshot
Table 74 : Siemens Healthineers AG: Financial Performance, FY 2022 and 2023
Table 75 : Siemens Healthineers AG: Product Portfolio
Table 76 : Siemens Healthineers AG: News/Key Developments, 2022
Table 77 : Telix Pharmaceutical Ltd.: Company Snapshot
Table 78 : Telix Pharmaceutical Ltd.: Financial Performance, FY 2022 and 2023
Table 79 : Telix Pharmaceutical Ltd.: Product Portfolio
Table 80 : Telix Pharmaceutical Ltd.: News/Key Developments, 2022–2024
Table 81 : Upcoming Startups in The Field of Theranostics

List of Figures

Summary Figure : Global Market for Theranostics, by Product Type, 2021–2029
Figure 1 : Theranostics Workflow
Figure 2 : Components of the Drug Approval Process
Figure 3 : Preclinical and Clinical Trials Phases
Figure 4 : Clinical Trials Radionuclide Pictorial Representative, 2024
Figure 5 : Market Dynamics of Theranostics
Figure 6 : Disadvantages of Chemotherapy Treatment
Figure 7 : Drug Development Cost, 2002 and 2022
Figure 8 : Global Market Shares of Theranostics, by Product Type, 2023
Figure 9 : Global Market Shares of Theranostics, by Product Type, 2029
Figure 10 : Global Market Shares of Theranostics Equipment, by Type, 2023
Figure 11 : Global Market Shares of Theranostics Agents, by Type, 2023
Figure 12 : Schematic Representation of Radionuclide Therapy
Figure 13 : Schematic Representation of Radionuclide Therapy
Figure 14 : Etiology of Cancer
Figure 15 : Cancer Diagnostics Methods
Figure 16 : Types of Imaging
Figure 17 : Asia-Pacific Cancer Incidence, 2008 and 2030
Figure 18 : Global Market Shares of Theranostics Instruments, by Installation Base, 2024
Figure 19 : Share of Clinical Trials, by Recruiting Status, 2024
Figure 20 : Share of Clinical Trials, by Type of Indication, 2024
Figure 21 : Share of Clinical Trials, by Phase, 2024
Figure 22 : Share of Clinical Trials, by Type of Funder, 2024
Figure 23 : Share of Clinical Trials, by Gender, 2024
Figure 24 : The Most Used Radioisotopes in Theranostics and Radioligand Clinical Trials, 2024
Figure 25 : ESG Concerns in the Theranostics Market
Figure 26 : Bayer AG: Revenue Share, by Business Unit, FY 2023
Figure 27 : Bayer AG: Revenue Share, by Country/Region, FY 2023
Figure 28 : GE Healthcare: Revenue Share, by Business Unit, FY 2023
Figure 29 : GE Healthcare: Revenue Share, by Country/Region, FY 2023
Figure 30 : Lantheus: Revenue Share, by Business Unit, FY 2023
Figure 31 : Novartis AG: Revenue Share, by Business Unit, FY 2023
Figure 32 : Novartis AG: Revenue Share, by Country/Region, FY 2023
Figure 33 : Siemens Healthineers AG: Revenue Share, by Business Unit, FY 2023
Figure 34 : Siemens Healthineers AG: Revenue Share, by Country/Region, FY 2023
Figure 35 : Telix Pharmaceutical Ltd.: Revenue Share, by Business Unit, FY 2023

BCC Research（BCCリサーチ）はライフサイエンス、センサ、マテリアル、環境、商取引関連市場を中心とした広範な市場調査レポートを出版する米国の調査会社です。

ライセンス別価格表

2024年11月より価格構成が大幅に変更になりました。最新の価格についてはお問合せください。

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

新価格表

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

旧価格表

旧ライセンスタイプ1

旧ライセンスタイプ2

ご購入に関するご案内

価格・納期について

• 価格
• ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • 2-5ライセンス
    • 同一企業内5名までレポートファイルのご利用が可能です。
  • サイトライセンス
    • 同一企業同住所内でレポートファイルのご利用が可能です。
  • エンタープライズライセンス
    • 同一企業内人数無制限でレポートファイルのご利用が可能です。
• 納品形態
  • Eメール
• 納期
  • ご注文後3営業日以内

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

BCC Researchが出版する調査レポートのサンプルページのご依頼、見積り、ご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 食品小売業およびEコマースにおけるAIの世界市場 2025-11-14
• 免疫療法薬の世界市場 2025-11-12
• 農業におけるAIの世界市場 2025-11-10
• 固体酸化物形燃料電池の技術と世界市場 2025-11-07
• 世界の電気アーク炉市場 2025-11-07

BCC Research  出版レポート一覧